189 related articles for article (PubMed ID: 20545875)
1. Post-marketing surveillance of methadone and buprenorphine in the United States.
Dasgupta N; Bailey EJ; Cicero T; Inciardi J; Parrino M; Rosenblum A; Dart RC
Pain Med; 2010 Jul; 11(7):1078-91. PubMed ID: 20545875
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
[TBL] [Abstract][Full Text] [Related]
3. Abuse and diversion of buprenorphine sublingual tablets and film.
Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
[TBL] [Abstract][Full Text] [Related]
4. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.
Davis JM; Severtson SG; Bucher-Bartelson B; Dart RC
Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):18-25. PubMed ID: 24130046
[TBL] [Abstract][Full Text] [Related]
5. Use and misuse of opioid agonists in opioid addiction.
Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
[TBL] [Abstract][Full Text] [Related]
6. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
Coplan PM; Sessler NE; Harikrishnan V; Singh R; Perkel C
Postgrad Med; 2017 Jan; 129(1):55-61. PubMed ID: 27922764
[TBL] [Abstract][Full Text] [Related]
7. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
Jaffe JH; O'Keeffe C
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S3-11. PubMed ID: 12738346
[TBL] [Abstract][Full Text] [Related]
8. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
Bonhomme J; Shim RS; Gooden R; Tyus D; Rust G
J Natl Med Assoc; 2012; 104(7-8):342-50. PubMed ID: 23092049
[TBL] [Abstract][Full Text] [Related]
9. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL
J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129
[TBL] [Abstract][Full Text] [Related]
10. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Neumann AM; Blondell RD; Jaanimägi U; Giambrone AK; Homish GG; Lozano JR; Kowalik U; Azadfard M
J Addict Dis; 2013; 32(1):68-78. PubMed ID: 23480249
[TBL] [Abstract][Full Text] [Related]
11. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Doernberg M; Krawczyk N; Agus D; Fingerhood M
Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Winstock AR; Lea T; Sheridan J
Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
[TBL] [Abstract][Full Text] [Related]
13. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Lugoboni F; Zamboni L; Cibin M; Tamburin S;
Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
[TBL] [Abstract][Full Text] [Related]
14. Increasing rates of buprenorphine diversion in the United States, 2002 to 2019.
Buttram ME; Kurtz SP; Margolin ZR; Severtson SG
Pharmacoepidemiol Drug Saf; 2021 Nov; 30(11):1514-1519. PubMed ID: 34302707
[TBL] [Abstract][Full Text] [Related]
15. The underrecognized toll of prescription opioid abuse on young children.
Bailey JE; Campagna E; Dart RC;
Ann Emerg Med; 2009 Apr; 53(4):419-24. PubMed ID: 18774623
[TBL] [Abstract][Full Text] [Related]
16. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
17. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
Johanson CE; Arfken CL; di Menza S; Schuster CR
Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.
Atluri S; Sudarshan G; Manchikanti L
Pain Physician; 2014; 17(2):E119-28. PubMed ID: 24658483
[TBL] [Abstract][Full Text] [Related]
19. The impact of the prescription opioid epidemic on young children: Trends and mortality.
Wang GS; Olsen H; Severtson G; Green JL; Dart RC
Drug Alcohol Depend; 2020 Jun; 211():107924. PubMed ID: 32178937
[TBL] [Abstract][Full Text] [Related]
20. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) System.
Zosel A; Bartelson BB; Bailey E; Lowenstein S; Dart R
J Am Acad Child Adolesc Psychiatry; 2013 Feb; 52(2):196-204.e2. PubMed ID: 23357446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
